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Abstract: Corticosteroids (CS) regulate many enzymes at both mRNA and protein levels. This study used microarrays to 
broadly assess regulation of various genes related to the greater urea cycle and employs pharmacokinetic/pharmacodynamic 
(PK/PD) modeling to quantitatively analyze and compare the temporal proﬁ  les of these genes during acute and chronic 
exposure to methylprednisolone (MPL). One group of adrenalectomized male Wistar rats received an intravenous bolus 
dose (50 mg/kg) of MPL, whereas a second group received MPL by a subcutaneous infusion (Alzet osmotic pumps) at a 
rate of 0.3 mg/kg/hr for seven days. The rats were sacriﬁ  ced at various time points over 72 hours (acute) or 168 hours 
(chronic) and livers were harvested. Total RNA was extracted and Affymetrix
® gene chips (RG_U34A for acute and RAE 
230A for chronic) were used to identify genes regulated by CS. Besides ﬁ  ve primary urea cycle enzymes, many other genes 
related to the urea cycle showed substantial changes in mRNA expression. Some genes that were simply up- or down-
regulated after acute MPL showed complex biphasic patterns upon chronic infusion indicating involvement of secondary 
regulation. For the simplest patterns, indirect response models were used to describe the nuclear steroid-bound receptor 
mediated increase or decrease in gene transcription (e.g. tyrosine aminotransferase, glucocorticoid receptor). For the bipha-
sic proﬁ  les, involvement of a secondary biosignal was assumed (e.g. ornithine decarboxylase, CCAAT/enhancer binding 
protein) and more complex models were derived. Microarrays were used successfully to explore CS effects on various urea 
cycle enzyme genes. PD models presented in this report describe testable hypotheses regarding molecular mechanisms and 
quantitatively characterize the direct or indirect regulation of various genes by CS.
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Introduction
Glucocorticoids (GC) are a class of steroid hormones produced by the adrenal glands that have diverse 
effects on carbohydrate, lipid, and protein metabolism. While they are important regulators of many 
developmental processes, immune system and tissue integrity (i.e. bone homeostasis), one of their major 
physiological roles is the regulation of systemic fuel supplies. This includes gluconeogenesis, the pro-
duction of glucose from non-carbohydrate sources (primarily glycerol from fat and amino acids from 
protein). When blood glucose from dietary sources and from breakdown of liver glycogen becomes 
inadequate, it is the gluconeogenic process that maintains glucose homeostasis. In order to meet this 
need, GC output occurs in a circadian pattern that mirrors the daily species requirement for increased 
glucose production. In situations of stress (where energy demands are increased), the adrenal output of 
GC is increased above normal levels in order to meet the demand.
The effects of GC on the immune system are exploited clinically in the use of synthetic corticoste-
roids (CS) as immunosuppressive/anti-inﬂ  ammatory agents. Corticosteroids are widely used to treat a 
variety of conditions, including organ transplantation, rheumatoid arthritis, lupus, and irritable bowel 
syndrome. However, such long-term use is associated with serious adverse effects that often reﬂ  ect a 
magniﬁ  cation of physiological hormone actions. The development of hypertension, steroid-induced 
diabetes, atherosclerosis, and muscle weakness can result from chronic CS therapy and to a large 
extent limits their usefulness as clinical agents. Ascertaining the complex multi-gene, multi-tissue effects 
of steroid treatment will provide a better understanding of how pharmacologically magnified 
steroid-induced alterations in gene expression result in complex systemic pathologies.2
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Corticosteroid-induced gluconeogenesis and 
insulin resistance provide the foundation for steroid 
diabetes. Only two tissues, the liver and kidney, 
are capable of gluconeogenesis. Gluconeogenesis 
from amino acid carbon in the kidney requires 
disposal of the resultant ammonia as ammonium 
ion. However, in the liver, gluconeogenesis from 
amino acid carbon requires detoxification of 
ammonia. This is accomplished in the liver by the 
urea cycle, which converts ammonia to urea. The 
general schematic of the urea cycle, adopted from 
Voet et al. (Voet and Voet, 1990), is shown in 
Figure 1. Urea synthesis alone requires five 
enzymes (arginosuccinate lyase, arginosuccinate 
synthetase, arginase, ornithine transcarbamoylase, 
and carbamoyl phosphate synthetase). In addition 
to these ﬁ  ve genes, we have deﬁ  ned the “greater 
urea cycle” and also examined the expression of 
mRNA for nine additional enzymes that play a 
role in the disposal of nitrogen in the liver 
(glutamine synthetase, glutamine dehydrogenase, 
malate dehydrogenase, carbonic anhydrase, 
glutaminase, ornithine decarboxylase, tyrosine 
aminotransferase, aspartate aminotransferase and 
alanine aminotransferase), and two additional 
genes involved in transcriptional regulation of 
those genes; glucocorticoid receptor (GR) and 
CCAAT/enhancer binding protein (CEBP-β).
Most GC effects are mediated at the molecular 
level by changes in the expression of speciﬁ  c 
mRNAs. Gene arrays can provide a method of 
high throughput data collection that is necessary 
for constructing comprehensive information on 
the transcriptional basis of complex systemic 
polygenic phenomena. When microarrays are 
used in a rich in vivo time series experiment they 
yield temporal patterns of changes in gene 
expression that illustrate the cascade of molecular 
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Figure 1. General schematic of greater urea cycle and its regulation by acute and chronic MPL. The arrows indicate MPL mediated 
up- (↑), down- (↓) or biphasic (↑↓: up-followed by down; ↓↑: down-followed by up) regulations.
Abbreviations: AA: Amino acids; ALT: Alanine aminotransferase; ARG: Arginase; ASL: Arginosuccinate lyase; aspAT: Aspartate aminotrans-
ferase; ASS: Arginosuccinate synthetase; ATP: Adenosine tri-phosphate; CA: Carbonic anhydrase; CEBP-β: CCAAT/enhancer binding 
protein; CPS: Carbamoyl phosphate synthetase; FUM: Fumerase; GA: Glutaminase; GDH: Glutamate dehydrogenase; Gln: Glutamine; Glu: 
Glutamate; GR: Glucocorticoid receptor; GS: Glutamine synthetase; α-KA: α-ketoacids; α-KG: α-ketoglutarate; MDH: Malate dehydrogenase; 
ODC: Ornithine decarboxylase; OTC: Ornithine transcarbamoylase; TAT: Tyrosine aminotransferase.
The enzyme genes in the boxes were analyzed in this study.3
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events in time that mediate broad multi-gene 
responses. Previously we described the mining 
and analysis of microarray time series illustrating 
the responses of liver, skeletal muscle, and kidney 
taken from the same set of animals to a single 
bolus dose of methylprednisolone (MPL) (Almon 
et al. 2005a; Almon et al. 2004; Almon et al. 
2005c). These time series included individual 
chips from multiple control animals as well as 
multiple animals at each of sixteen times over a 
72 hour period following bolus dosing with MPL. 
Because these experiments were initiated using 
adrenalectomized animals, the drug in essence 
acts as a stimulus that perturbs the homeostatic 
balance of the system, and the deviation of the 
system and its return to the original state were 
monitored. Among the genes identiﬁ  ed as GC 
regulated were the 16 genes previously designated 
as the “greater urea cycle”.
Although very useful, a single time series only 
views the dynamics of the system in response to 
the one stimulus. A pharmacological time series 
differs from most time series studies (for example 
those assessing developmental changes) in that it 
can be evaluated using a different dosing regimen. 
The results from both phases can be used to group 
genes into clusters with common mechanisms of 
regulation. If two or more genes have a common 
mechanism of regulation, then their response 
proﬁ  les should be the same regardless of the 
dosing regimen. With such data, the challenge 
then becomes one of constructing rational, 
quantitative, mechanism-based frameworks that 
describe the relationships between the elements 
of the cascades. Kinetic/dynamic modeling 
provides quantitative, testable, mechanism-based 
hypotheses concerning the relationship between 
drug kinetics and elements of cascades that 
continue long after the drug has dissipated. Such 
models can accommodate hierarchal cascades 
where one process generates effectors or mediators 
for other processes. They can also accommodate 
convergence of cascades that commonly occur in 
the control of the expression of genes where 
binding sites for multiple nuclear factors 
participate in the regulation of the level of 
expression of a particular mRNA. This mRNA in 
turn becomes an endogenous mediator for the 
expression of proteins that may become effector 
molecules for other processes. Here, we present 
the dynamic picture of steroid modulation of 
expression of the “greater urea cycle” (Fig. 1).
Materials and Methods
Experimental
Livers were obtained from animal studies per-
formed in our laboratory (Ramakrishnan et al. 
2002; Sun et al. 1998a). In the acute study, male 
ADX Wistar rats weighing 225–250 g (Harlan 
Sprague-Dawley Inc., Indianapolis) were subjected 
to right external jugular vein cannulation under 
light ether anesthesia one day prior to the study. A 
single intravenous (IV) bolus dose of 50 mg/kg 
MPL (Solu-Medrol, Pharmacia-Upjohn Company, 
MI) was given to 47 animals via the cannula. Rats 
were sacriﬁ  ced by aortic exsanguination at 0.25, 
0.5, 0.75, 1, 2, 4, 5, 5.5, 6, 7, 8, 12, 18, 30, 48 and 
72 hr. The sampling time points were selected 
based on previous studies of receptor dynamics 
and enzyme induction in muscle and liver 
(Ramakrishnan et al. 2002; Sun et al. 1998a; Sun 
et al. 1998b). Four vehicle-treated rats were des-
ignated as controls and were considered as 
sacriﬁ  ced at time point zero.
In the chronic-dosing study, 40 male ADX 
Wistar rats weighing 300–350 g were given 0.3 
mg/kg/hr infusions of MPL reconstituted in 
supplied diluent. The infusions were given using 
Alzet osmotic pumps (Model 2001, ﬂ  ow rate 
1 ul/hr; Alza, Palo Alto, CA). The pump drug 
solutions were prepared for each rat based on its 
pre-dose body weight. Pumps were implanted 
subcutaneously between the shoulder blades on 
the back. Four rats were sacriﬁ  ced by aortic 
exsanguination at 6, 10, 13, 18, 24, 36, 48, 72, 
96, and 168 hr. Four control rats were implanted 
with a saline-filled pump and sacrificed at 
selected times throughout the 7-day study 
period.
Blood samples were collected from the abdom-
inal aorta, centrifuged to harvest plasma, and stored 
at −80 °C until analysis of plasma MPL. Livers 
were rapidly excised, quickly frozen in liquid 
nitrogen, and stored at −80 °C.
Drug assay
MPL plasma concentrations were measured 
by a previously described normal-phase high 
performance liquid chromatography (HPLC) 
method (Haughey and Jusko, 1988). The lower 
limit of quantiﬁ  cation was 10 ng/ml with inter- and 
intra-day assay variability less than 10%.4
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RNA extraction and labeling
Frozen livers were ground into powder using a 
mortar and pestle chilled with liquid nitrogen. Total 
RNA extractions were carried out by a Trizol-
chloroform based extraction method. About 
100 mg of ground liver from each animal was 
added to prechilled Trizol Reagent (Invitrogen, 
Carlsbad, CA) at a ratio of tissue: Trizol of 1:10. 
Extractions were performed according to 
manufacturer protocols. Extracted RNA was 
further puriﬁ  ed by passage through RNAeasy mini-
columns (Qiagen, Valencia, CA). Final extracted 
RNA samples were resuspended in nuclease-free 
water. Quantity of total RNA was determined by 
spectrophotometry and purity was assessed by 
agarose gel electrophoresis. Extracted total RNA 
preparations were stored at −80 °C.
Microarrays
Isolated liver RNA from each individual animal 
was used to prepare biotinylated cRNA target 
according to manufacturer protocols. Then bioti-
nylated cRNAs from the acute study were 
hybridized to 51 (47 treated and 4 control animals) 
individual Affymetrix GeneChips
® Rat Genome 
U34A (Affymetrix, Santa Clara, CA), which 
contained 8799 probe sets. The target cRNAs from 
the chronic study were hybridized to 44 (40 treated 
and 4 control animals) individual Affymetrix 
GeneChips
® Rat Genome 230A (Affymetrix, Santa 
Clara, CA), which contained 15967 probe sets. 
Oligonucleotide microarrays were utilized because 
of their high reproducibility between separate 
arrays. The entire data set was submitted to 
the National Center for Biotechnology Information 
(NCBI) Gene Expression Omnibus database 
(GDS253 and GDS972) and is also available online 
at http://pepr.cnmcresearch.org/ (Almon et al. 
2003). Our approach to identifying probes of inter-
est has been described in previously published 
articles on mining the datasets for muscle, liver, 
and kidney from the acute MPL treated animals 
(Almon et al. 2005a; Almon et al. 2004; Almon 
et al. 2005c). Literature searches of the 1512 probe 
sets identiﬁ  ed as regulated in the acute liver data-
set yielded 16 probe sets for 16 genes relevant to 
ammonia detoxification. Probe sets for these 
16 genes were also present on the 230A chip and 
used to analyze the livers following chronic infu-
sion. These probe sets were statistically examined 
by ANOVA with a Tukey posthoc test (p   0.05) 
using GeneSpring 7.0 software (Silicon Genetics, 
Redwood City, CA) and were signiﬁ  cantly differ-
ent when compared with the control animals.
Data from both acute and chronic studies were 
simultaneously modeled. The data for each probe 
set were transformed so that the values for all 
probe sets were within the same range. To accom-
plish this, individual probe set values on each chip 
were divided by the mean of the four control values 
for that gene. Thus, the “normalized intensity” for 
each probe set has a value of 1 at zero time and either 
decreases, increases, or remains the same when 
compared to the controls over the time series.
Pharmacokinetics
The PK of MPL for both the bolus and infusion 
regimens were described by a two-compartment 
model with a zero-order input k0 into the central 
plasma compartment for the infusion regimen as 
given below:
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where Ap and At are the amounts of drug in the 
plasma and tissue compartments. The k12, k21 and 
Vp are the distribution rate constants and central 
volume of distribution; CL is clearance. These 
parameters were ﬁ  xed based on previous literature 
values (Ramakrishnan et al. 2002; Sun et al. 
1998a). For the i.v. bolus kinetics, the same equa-
tions were used with deletion of k0 and use of 
Ap(0) = Dose. The kinetic parameters were ﬁ  xed 
(Table 1) and were used as the driving force for 
the dynamic modeling.
Receptor dynamics
Glucocorticoid receptor dynamics in liver following 
single IV 50 mg/kg MPL dosing was previously 
described by a mechanistic receptor-gene mediated 
pharmacodynamic model (Fig. 2). The present 
model was developed using the assumption that 
being moderately lipophilic, unbound MPL diffuses 
through cell membranes and binds with cytosolic 
free glucocorticoid receptors (GR). Drug-receptor 
complex (DR) then translocates into the nucleus 5
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(nuclear DR: DR(N)) where it dimerizes and binds 
to a speciﬁ  c glucocorticoid response element (GRE) 
in the target DNA. The binding of DR(N) and GRE 
enhances or inhibits the expression of target genes. 
The CS are known to inhibit the expression of their 
own receptors (Dong et al. 1988) by homologous 
down-regulation. After dissociation from DNA, GR 
receptors are recycled into cytosol, where receptors 
are either degraded or further activated by MPL 
(Oakley and Cidlowski, 1993; Sun et al. 1998a). 
The equations describing the model are:
 
dmRNA
dt
k
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IC DR N
k
GR
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Table 1. Pharmacokinetic and receptor dynamic parameters.
Parameters Deﬁ  nitions  Values
CL (L/hr/kg) Clearance  5.61
a/3.48
b
Vp (L/kg) Central  Volume  0.82
a/0.73
b
k12 (h
−1) Distribution  rate  constant  0.32
a/0.98
b
k21 (h
−1) Distribution  rate  constant  0.69
a/1.78
b
ksyn,GRmRNA (fmol/g/hr)  GR mRNA synthesis rate constant  3.15
a/0.45
kdgr,GRmRNA(h
−1)  GR mRNA loss rate constant  0.122
IC50 (nmol/L/mg protein)  DR(N) required for 50% inhibition of ksyn,GRmRNA 123.7
kon (L/nmol/hr)  Association rate constant for steroid GR binding  1.9.10
−2
kT (h
−1) Translocation  constant  58.1
kre (h
−1)  Loss rate constant for DR(N)  0.402
Rf Recycling  factor  0.690
ksyn,GR(nmol/L/mg  GR synthesis rate constant  0.84
a/3.63
b
protein/fmole GRmRNA/g/hr)
kdgr,GR (h
−1)  GR loss rate constant  0.0403
mRNA
0
GR (fmol/g) GR  mRNA  baseline  25.8
a/3.65
b
R
0 (fmol/mg protein) GR  baseline  540.7
a/328.7
b
aAcute; 
bChronic.
IC50
(1-Rf). kre
DR(N)
DR
Rf. kre
kon kT
+ R
kdgr,GR
ksyn,GR
Df
mRNAGR
kdgr,GRmRNA ksyn,GRmRNA
Figure 2. Pharmacodynamic model for glucocorticoid receptor dynamics upon CS administration. The symbols are deﬁ  ned in 
Eq. (3)–(8). The dotted line and the solid rectangle depict inhibition by an indirect mechanism.6
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where symbols represent cytosolic free plasma 
MPL (CMPL,f) where the unbound fraction of MPL 
was ﬁ  xed to 0.23 (Kong and Jusko, 1991), free 
glucocorticoid receptor density (R), GR mRNA 
(mRNAGR), cytosolic GR-drug complex (DR), GR-
drug complex in nucleus (DR(N)), zero-order GR 
mRNA synthesis rate constant (ksyn,GRmRNA), and 
ﬁ  rst-order rate constants for GR mRNA degrada-
tion (kdgr,GRmRNA), GR synthesis (ksyn,GR) and GR 
degradation (kdgr,GR). Other rate constants include: 
second-order association rate constant of GR and 
drug (kon), translocation rate constant of DR from 
cytosol to nucleus (kT), and the overall turnover 
rate of DR(N) (kre). The fraction of GR that is 
recycled from nucleus to cytosol (Rf) can be further 
activated by association of drug. Thus (1−Rf) is the 
fraction of GR that is degraded during one cycle 
of drug-receptor complex translocation. The IC50 
is the concentration of DR(N) at which the synthe-
sis rate of GR mRNA is reduced to 50% of its 
baseline level.
Assuming that in the absence of drug the 
mRNAGR remains constant, the synthesis rate is:
  kk m R N A syn GRmRNA dgr GRmRNA GR ,, () =⋅ 0  (7)
Also in the absence of drug assuming that 
R0 is constant, the translational rate constant 
ksyn,GR is:
  k
R
mRNA
k syn GR
GR
dgr GR ,
()
, =
⎛
⎝
⎜
⎞
⎠
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0
 (8)
The values for the baselines of both the GR mRNA 
and the receptors were ﬁ  xed and were obtained 
from Sun et al. (Sun et al. 1998a; Sun et al. 1998b). 
The baseline values for DR and DR(N) are zero. 
The detailed analysis of receptor dynamics (param-
eters given in Table 1) were done elsewhere (Hazra 
et al. 2007) and were ﬁ  xed to drive further dynamic 
modeling.
Pharmacogenomic modeling
In the present report we measured drug kinetics, 
GR concentration, GR mRNA concentration, and 
the normalized concentrations of 16 mRNAs, some 
of which are transcription factors that in turn 
become factors controlling the expression of genes. 
Since mRNAs have natural turnover processes, we 
have used various inhibitory or stimulatory models 
(Dayneka et al. 1993) to describe the primary or 
secondary regulation of these genes by CS.
Most of the metabolic effects of CS have been 
attributed to its classical model of action where 
binding of nuclear hormone-bound GR complexes 
to the regulatory regions of various target genes 
causes stimulation or inhibition of expression of 
these genes. Many of the genes related to nitrogen 
metabolism are known to have GREs in their pro-
moter regions and therefore presumably are 
directly affected by binding of the nuclear drug-
bound receptor to these regions. However, it has 
also been found that CS causes changes in gene as 
well as protein expression of transcription factors 
such as C/EBP-β or HNF-3 (Gotoh et al. 1997; 
Morris, 1992; Schoneveld et al. 2004) which are 
also strong regulators of various urea cycle genes. 
As a result both primary (mediated by GR binding 
GREs in promoter regions of target genes) as well 
as the secondary transcriptional regulation are pas-
sive mechanisms for GC modulation of mRNA 
expression.
Both mechanisms were taken into consideration 
to develop models to describe the dynamics of 
various genes related to the greater urea cycle after 
acute and chronic MPL. Many of the genes show-
ing simple up- or down-regulation after acute 
dosing seemed to have complex patterns after 
chronic dosing. Our aim was to build models 
which were able to simultaneously describe 
the time profiles of these genes after both 
treatments.
In the absence of drug, all the genes were 
assumed to be synthesized at a zero-order rate 
(ksyn,Enzm) and degraded with a ﬁ  rst-order rate con-
stant (kdgr,Enzm) as follows:
  dmRNA
dt
kkm R N A syn Enz dgr Enz mm =−⋅ ,,
 (9)7
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Since the rats were adrenalectomized, the genes 
under consideration were assumed to have a sta-
tionary baseline (mRNA0) in the absence of the 
drug (control animals), thereby allowing ksyn,Enzm 
to be calculated from:
  kk m R N A syn Enz dgr Enz mm ,, =⋅ 0  (10)
All mRNA baselines were ﬁ  xed to 1.0 except for 
the cases where estimation of this parameter 
improved the model ﬁ  ttings signiﬁ  cantly (assessed 
by visual inspection and AIC, SC criteria).
Stimulation of transcription
This characteristic was assumed to be mediated by 
the stimulatory effect of DR(N) on the synthesis 
rate of mRNA. Two conditions may arise; either 
the stimulation by DR(N) may be linear, non-
saturable (Fig. 3A) in nature for a given gene or 
dose of the drug (Eq. 11a) or it could be a saturable 
function (Fig. 3B) where the effect of the drug is 
limited by capacity-limited factors such as Smax and 
SC50 (Eq. 11b) as given by:
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where S is a linear stimulation constant by which 
DR(N) increases the synthesis of the enzyme 
mRNA, SC50 is the concentration of DR(N) respon-
sible for 50% of maximum stimulation, and Smax 
is the maximum stimulation capacity.
Biphasic regulation
Two different models were developed to describe 
biphasic regulation. In the ﬁ  rst model as depicted 
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Figure 3. Pharmacogenomic models for CS effects on genes related to urea cycle via various mechanisms. Models A to F are deﬁ  ned 
in detail in the Methods section and with Eq. 9–16. The rectangles indicate stimulation (open bar) and inhibition (solid bar) of the various 
processes via indirect mechanisms.8
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in Figure 3C, DR(N) linearly stimulates the 
production of the enzyme mRNA whereas a 
biosignal (BS) derived from DR(N) is responsible 
for secondary inhibition of the production as 
given by:
  dBS
dt
DR N BS e =− ( ) k ()  (12)
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dt
kS D R N
BS
IC BS
k
syn,Enz
50
dgr,Enz
m =+ ⋅ ()
−
+
⎛
⎝ ⎜
⎞
⎠ ⎟
−
1( )
1 .
γ
γγ
m m mRNA ⋅
  (13)
where ke is a ﬁ  rst-order transduction rate constant 
accounting for the delayed formation of BS from 
DR(N), S is a linear stimulation constant by which 
DR(N) stimulates the production rate constant, IC50 
is the concentration of BS responsible for 50% 
inhibition of the mRNA synthesis rate, γ is a factor 
describing ampliﬁ  ed effects of BS on the production 
of mRNA. In the absence of the drug, the BS value 
is set to zero.
In the second model, described in Figures 3D 
and 3E, the DR(N) increases the degradation of 
mRNA, whereas the biosignal (Eq. 12) derived 
from the DR(N) is responsible for a delayed 
increased (either linear or non-linear) production 
of the mRNA as given by:
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where SBS is the linear constant, Smax and SC50 are 
the capacity-limited stimulatory constants by 
which BS increases the production rate constant, 
and SDR(N) is the linear stimulation constant by 
which DR(N) regulates the degradation rate 
constant for mRNA.
Down-regulation
As depicted in Figure 3F, down-regulation of 
mRNA was described by:
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IC DR N
k
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()
() 50
,,G R .mRNA
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where IC50 is the DR(N) concentration at which 
mRNA synthesis rate reduces to 50% of its baseline 
value.
Scaling Factor
Since two types of chips were used for the acute 
and chronic studies, a factor (SF) was incorporated 
in the chronic study data (Ychronic) to account for 
the possible difference in sensitivity between the 
probe sets (Yao et al. 2007):
  Ym R N A chronic chronic
SF
= ()  (17)
where mRNAchronic is the data (from 230A chips) 
for the gene of interest after chronic infusion of 
MPL.
Data for each gene from both the acute and 
chronic studies were ﬁ  tted simultaneously with 
ADAPT II software (D’Argenio, 1997) using the 
Maximum Likelihood method, where the variance 
model was described as:
  Var t Y t ii (,,) (,) σθ σ θ
σ =⋅ 1
2 2  (18)
where Y represents the predicted value; σ1 and σ2 
are the variance parameters which were ﬁ  tted, and 
θ represents the structural parameters. The good-
ness of the ﬁ  t was assessed by model convergence, 
visual inspection, Akaike Information Criterion 
(AIC), Schwarz Criterion (SC), estimator criterion 
value, and examination of residuals.
Results
Pharmacokinetics and receptor dynamics
The experiments were initiated by MPL dosing. 
Although the kinetic data for both regimens have 
been previously published (Ramakrishnan et al. 
2002; Sun et al. 1998a), simulated pharmacokinetic 9
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proﬁ  les for both are provided as they represent the 
initial driving force for the dynamic models 
(Fig. 4). Figure 4a shows the simulations of MPL 
kinetics, DR, and DR(N) following the acute dose 
of MPL. Although the experiment continued for 
72 hours, the ﬁ  gure is truncated at 20 hours because 
MPL reached its lower limit of quantiﬁ  cation by 
6 hr and the drug-receptor complexes returned to 
their baseline prior to this time. Figure 4b shows 
the simulation of GR and GR mRNA which is also 
based on previously published data (Sun et al. 
1998b). Figure 4c shows the simulations of MPL 
kinetics, DR, and DR(N) during chronic infusion 
of MPL. This graph only shows the ﬁ  rst 48 hours 
of the 168 hour infusion period because all three 
variables reached a steady-state by this time. 
Figure 4d shows the simulation of GR and GR 
mRNA during chronic infusion which is also based 
on previously published data (Ramakrishnan et al. 
2002). The steady-state concentration after the 
chronic dosing (i.v. infusion) was 100-fold less 
than the bolus dose study. The clearance (3.48 to 
5.61 L/hr) difference could be attributed to the 
saturation of the metabolizing enzymes at the high 
dose. The DR(N) is used as the driving force regu-
lating many of the genomic effects of CS.
Pharmacogenomic modeling
The dynamics of most of the genes showed more 
complex regulation during chronic infusion of 
MPL compared to acute bolus dosing. Based on 
the time proﬁ  les from the acute dosing study the 
genes of the greater urea cycle could be divided 
into three main classes, up-regulated, biphasic, 
and down-regulated. These could be further divided 
into various sub-categories based on the chronic 
dataset.
Class 1
This class is comprised of four genes which were 
up-regulated in response to both acute and chronic 
administration of MPL. Model A or B (shown in 
Fig. 3), where the transcription is assumed to be 
increased by DR(N), was used to capture the 
general trend of the data (Fig. 5). The dynamics of 
A) B)
C) D)
Figure 4. Time proﬁ  les of various components in MPL pharmacokinetics and receptor dynamics. Lines are simulations with the model 
given in Figure 2 after 50 mg/kg MPL i.v. injection (4A and B) or 0.3 mg/kg/hr chronic infusion for seven days (4C and D) in ADX rats using 
parameters listed in Table 1.10
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tyrosine aminotransferase (TAT) was described by 
Model A as discussed in previous reports based on 
measurements by other methods (Ramakrishnan 
et al. 2002; Sun et al. 1998a). The degradation rate 
constant (kdgr,Enz) for TAT mRNA, 0.503 hr
−1 
closely resembled the reported value of 0.383–
0.533 hr
−1 (Ramakrishnan et al. 2002; Sun et al. 
1998a). The other three genes in this class, aspar-
tate aminotransferase (aspAT), argininosuccinate 
synthetase (ASS), and malate dehydrogenase 
(MDH), were described more accurately by Model 
B with capacity-limited stimulation by DR(N). The 
apparent tolerance observed for TAT and aspAT 
(Fig. 5a) was not observed for ASS or MDH 
(Fig. 5b), which can be explained by much lower 
values for SC50 (Table 2) for the latter two genes 
(4.1 and 14.0 nM) compared to aspAT (107.4 nM). 
The variation in the degree of stimulation (normal-
ized signal ranging from 2.5–12) of the messages 
was also reﬂ  ected by their respective Smax values, 
ranging from 0.76 to 7.3 (fmol/mg protein)
−1. The 
precisions of the estimated parameters were rea-
sonable with the exception of the SC50 values for 
ASS and MDH. The scaling factors for all four 
genes ranged between 1 and 3 and were estimated 
with good precision.
Class 2
The genes in this group are also up-regulated with 
acute dosing, but show a biphasic pattern with 
chronic dosing. The biphasic pattern is more appar-
ent for ornithine decarboxylase (ODC) and 
CCAAT/enhancer binding protein (CEBP-β) than 
ASL, suggesting possible existence of dual mech-
anisms in the regulation of these genes. Model C, 
where the initial increase in the message is assumed 
to be mediated by DR(N) followed by a decline 
driven by a biosignal or a feedback regulator, best 
described (among other models tested) the general 
trend of the data for all three genes (Fig. 6) with 
relatively good precision for the estimated param-
eters. Since the biphasic trend is not quite apparent 
for argininosuccinate lyase (ASL), Models A and 
B were tested for this gene, however, Model C 
resulted in best ﬁ  t of the data from visual inspection 
and model selection criteria such as AIC and SC 
values. The model-ﬁ  tted parameters for all three 
genes are given in Table 3. Since the transduction 
parameter, ke for CEBP-β could not be estimated 
with reasonable precision, it was ﬁ  xed to an optimum 
value of 0.1 (upon performing sensitivity analysis). 
The degradation rate constant, kdgr,Enzm for ODC 
(0.14 hr
−1) was estimated to be somewhat lower 
than previously reported (0.3 hr
−1) by Jin et al. (Jin 
et al. 2003), however, use of a different as well as 
more complex model could contribute to this dif-
ference. Although the IC50 values for inhibition of 
the message by the biosignal were quite similar 
between these genes (ranging from 65–76.6 nM), 
the values for the ampliﬁ  cation factor, γ, were much 
higher than 1.0 and had signiﬁ  cant variation rang-
ing from 3.9 for ASL to 14.7 for ODC. The scaling 
factors for this group of genes were close to 1.0 
with CV less than 20%.
Class 3
This group of ﬁ  ve genes showed an early down-
regulation following acute MPL and a later and 
sustained up-regulation. However, during chronic 
infusion stimulation of the messages was pre-
dominant, except for glutamate dehydrogenase 
(GDH) and ornithine transcarbamoylase (OTC). 
It is important to note that for chronic infusion, 
the ﬁ  rst sampling was at 6 hr following initiation 
of infusion. Therefore, it is possible to miss 
the initial down-regulated phase seen in the acute 
response proﬁ  les. Models D and E, where the 
nuclear drug-receptor complex (DR(N)) mediates 
the initial decline followed by an up-regulation 
caused by a mediator, BS, derived from DR(N), 
could adequately capture the biphasic patterns of 
these genes both after acute and chronic admin-
istration. A linear stimulation constant (Model D) 
was sufﬁ  cient to describe the biosignal mediated 
increase in OTC, alanine aminotransferase(ALT) 
and carbamoyl phosphate synthetase (CPS). How-
ever, similar to genes in Class 1 (ASS and MDH), 
we observed a lack of tolerance in arginase (ARG) 
and GDH. Model E with saturable stimulation 
factors (Smax and SC50) yielded better ﬁ  ttings 
compared to Model D for these two genes when 
evaluated by various ﬁ  tting criteria. The estimated 
parameters from model fittings are shown in 
Table 4. For the three genes which were character-
ized by Model D, most of the estimated param-
eters, especially kdgr,Enzm (0.034–1.0 hr
−1), SDR(N) 
(0.004–0.027 nM
−1) and ke (0.03–1.1 hr
−1) varied 
between the genes, however, the parameters esti-
mated were usually associated with higher CV%. 
For the two genes, arginase and GDH (Fig. 8), 
which could be best described by Model E, the 
SC50 parameters could not be estimated with 11
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Figure 5a. Representative ﬁ  ttings of Class 1 genes. Solid circles are the mean data with standard deviations. Solid lines are ﬁ  ttings with 
Model A for TAT (Eq. (11a)) and Model B for aspAT (Eq. (11b)) for each individual gene after MPL administration. The estimated parameters 
are listed in Table 2.
Figure 5b. Representative ﬁ  ttings of Class 1 genes. Solid circles are the mean data with standard deviations. Solid lines are ﬁ  ttings with 
Model B for ASS and MDH (Eq. (11b)) for each individual gene after MPL administration. The estimated parameters are listed in Table 2.
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reasonable precision and were ﬁ  xed to optimum 
values based on the various ﬁ  tting criteria. Due 
to the variability associated with data for GDH, 
both ke and SC50 values could not be estimated 
with good precision and therefore were ﬁ  xed 
based on the estimates for the rest of the param-
eters. Thus the apparent high values for ke (10 hr
−1) 
and SC50 (100 nM
−1) for GDH should be inter-
preted with caution. One of the primary reasons 
for the high CV% of the estimated parame-
ters could be attributed to possible over-
parameterization of the model with the limited 
amount of data.
Classes 4A and 4B
Acute dosing of MPL causes down-regulation for 
this class of genes which can be captured by Model 
F where DR(N) inhibits the production rate (ksyn, 
Enzm) of the mRNA. For glucocorticoid receptor 
(GR) we could observe (Fig. 9) similar down-
regulation upon chronic infusion thus acute and 
chronic dataset could be ﬁ  tted simultaneously 
(Class 4A) using Model F with good ﬁ  tting results 
evaluated by various criteria. For glutaminase (GA) 
and carbonic anhydrase (CA), although an appar-
ent down-regulation was observed after acute 
administration without any indication of a biphasic 
Table 2. Estimated pharmacogenomic parameters for Class 1 genes.
Parameters Deﬁ  nitions  TAT  ASP-AT  ASS  MDH
     Estimate  (CV%) 
kdgr,Enz (hr
−1)  Loss rate of gene  0.448 (32.5)  0.81 (27.5)  0.15 (62.6)  0.066 (52.9)
SDR(N) (fmol/  Linear stimulation   0.003 (26.6)  –  –  –
mg protein)
−1  constant
Smax (fmol/  Maximum stimulation  –  7.5 (34.4)  1.34 (50.9)  0.95 (75.9)
mg protein)
−1
SC50 (nM)  Half-maximal DR(N)  –  107.4 (72.3)  4.1 (304)  14.0 (311)
SF  Scaling factor  2.7 (33.9)  1.6 (18.3)  1.14 (34.7)  1.6 (29.6)
Enzm0,acute  Baseline-Acute  0.89 (10.7)  1.0 (8.3)  0.93 (8.0)  1.0 (5.0)
Enzm0,chronic  Baseline-Chronic  1.05 (7.0)  1.02 (19.2)  0.97(16.1)  1.0 (5.0)
Figure 6. Fittings of Class 2 genes. Solid circles are the mean data with standard deviations. Solid lines are ﬁ  ttings with Model C 
(Eq. (12)–(13)) for each individual gene after MPL administration. The estimated parameters are listed in Table 3.13
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Table 3. Estimated pharmacogenomic parameters for Class 2 genes.
Parameters Deﬁ  nitions  ODC  ASL  CEBP
     Estimate  (CV%)   
ke (hr
−1)  Transduction rate   0.05 (8.7)  0.026 (35.7)  0.1 (ﬁ  xed)
 constant
kdgr,Enz (hr
−1)  Loss rate of gene  0.146 (15.2)  0.413 (27.4)  0.074 (21.5)
S (fmol/mg   Linear stimulation   0.06 (16.8)  0.009 (16.7)  0.04 (22.4)
protein)
−1  constant
γ Hill  coefﬁ  cient  13.6 (28.0)  3.8 (121)  5.2 (22.8)
IC50 (nM)  Half-maximal DR(N)  66.1 (2.0)  76.0 (34.3)  70.4 (9.1)
SF  Scaling factor  0.70 (8.4)  1.5 (13.1)  1.1 (11.9)
Enzm0,acute Baseline-Acute 1  (ﬁ  xed)  1 (ﬁ  xed)  1 (ﬁ  xed)
Enzm0,chronic  Baseline-Chronic  0.99 (10.4)  1 (ﬁ  xed)  1 (ﬁ  xed)
pattern, chronic infusion revealed a delayed and 
sustained up-regulation (Fig. 10) in the gene pro-
ﬁ  les. This suggests an existence of dual mecha-
nisms after continuous exposure of the drug. No 
suitable model could explain these differences 
simultaneously and therefore, only the acute 
dataset were ﬁ  tted with Model F. The estimated 
parameters for these three genes are given in 
Table 5. The estimated degradation rate constant 
for GR mRNA was very similar to previously 
reported values based on data from Quantitative 
Northern Hybridization measurements (Sun et al. 
1998a; Sun et al. 1998b). Most of the parameters 
could be estimated with reasonable precision with 
CV% less than 30%.
Discussion
Corticosteroids, either alone or in conjunction with 
transcription factors/hormones affect a wide array 
of genes responsible for regulating various physi-
ological processes. Recently oligonucleotide 
Figure 7. Fittings of Class 3 genes. Solid circles are the mean data with standard deviations. Solid lines are ﬁ  ttings with Model D 
(Eq. (12)–(14)) for each individual gene after MPL administration. The estimated parameters are listed in Table 4.14
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microarrays were successfully used in our lab to 
examine these diverse effects of corticosteroids 
from two sets of animal studies, which allowed us 
to evaluate changes in an enormous number of 
genes in various tissues simultaneously after acute 
(Almon et al. 2004; Almon et al. 2005c; Jin et al. 
2003) and chronic MPL. While such evaluations 
are quite helpful in determining which genes are 
affected by steroids in rats, another important 
aspect of such experiments is speciﬁ  c disease/ 
Table 4. Estimated pharmacodynamic parameters for Class 3 genes.
Parameters Deﬁ  nitions  CPS  ALT  OTC  ARG  GDH
       Estimate  (CV%) 
ke (h
−1)  Transduction rate   1.01 (44.3)  0.034 (15.6)  0.064 (124)  0.23 (42.1)  10 (ﬁ  xed)
 constant
kdgr,Enz (h
−1)  Loss rate of gene  0.039 (64.7)  0.521 (47.6)  0.04 (178)  1.75 (117)  0.25 (57.2)
SBS (fmol/mg   Linear stimulation   0.027 (84.8)  0.044 (27.6)  0.015 (132)  –  –
protein)
−1  constant by BS
Smax (fmol/mg   Maximum stimulation  –  –  –  1.5 (38.8)  2.64 (54.2)
protein)
−1
SC50 (nM)  Half-maximal DR(N)  –  –  –  11.0 (ﬁ  xed)  100 (ﬁ  xed)
SDR(N) (fmol/mg   Linear stimulation   0.023 (92.8)  0.004 (31.9)  0.012 (172)  0.005 (38)  0.008 (50.1)
protein)
−1  constant by DR(N)
SF  Scaling factor  3.5 (37.7)  3.2 (14.7)  1.24 (42.1)  1.9 (24.7)  2.59 (36.6)
Enzm0,acute Baseline-Acute  1  (ﬁ  xed)  1 (ﬁ  xed)  0.81 (7.03)  1 (ﬁ  xed)  1 (ﬁ  xed)
Enzm0, chronic Baseline-Chronic  1  (ﬁ  xed)  1 (ﬁ  xed)  1.16 (8.7)  1 (ﬁ  xed)  1 (ﬁ  xed)
Figure 8. Fittings of Class 3 genes. Solid circles are the mean data with standard deviations. Solid lines are ﬁ  ttings with Model E 
(Eq. (12)–(15)) for each individual gene after MPL administration. The estimated parameters are listed in Table 4.15
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physiological process based evaluation of the data 
as demonstrated by Almon et al. who examined 
the effects of MPL on insulin resistance speciﬁ  c 
genes (Almon et al. 2005b) in rat muscle. In this 
report, we investigated the dynamics of various 
genes related to the greater urea cycle, an important 
biochemical pathway present in mammalian livers 
for nitrogen disposal. Many of these enzymes are 
known to be highly regulated by CS in the liver 
(Christowitz et al. 1981; de Groot et al. 1984; 
Gautier et al. 1985).
The dynamics of many of these genes following 
acute dosing were previously reported from our 
lab (Jin et al. 2003). However simultaneous analy-
ses of both the acute and chronic dataset revealed 
more complex gene regulations which were not 
apparent after only single high-dose MPL.
Class 1 and Class 4A were the simplest regula-
tion patterns apparent amongst all the classes. TAT, 
which facilitates the transfer of an amino group 
from amino acid breakdown to the urea cycle and 
is also one of the most highly studied biomarkers, 
could be classiﬁ  ed as one of the Class 1 genes. 
Both TAT and glucocorticoid receptor (Class 4A) 
dynamics had extensively been studied in our lab 
(both at mRNA and protein levels) and ﬁ  ve gen-
erations of highly mechanistic, quantitative PK/PD 
models were developed for MPL at various dose 
levels (Ramakrishnan et al. 2002; Sun et al. 1998a; 
Figure 9. Fitting results of gene array data for glucocorticoid 
receptor. Solid circles are the mean data with standard deviations. 
Solid lines are ﬁ  ttings with Model F (Eq. (16)) after MPL administra-
tion. The estimated parameters are listed in Table 5.
Figure 10. Fittings of Class 4B genes. Solid circles are the mean data with standard deviations. Solid lines are ﬁ  ttings with Model F   
(Eq. (14)) for each individual gene after MPL administration. The estimated parameters are listed in Table 5.16
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Sun et al. 1998b). Thus the presence of these two 
genes in our database not only had importance with 
respect to their involvement in the urea cycle, but 
also allowed us to compare the results from the 
microarrays to previous measurements by quanti-
tative Northern Hybridization. For TAT the cor-
relations (R) between these two techniques were 
quite high for both acute (0.68) and chronic (0.87) 
dosing while for GR the correlation was less than 
0.5 which could be attributed to the much lower 
abundance of this message, the presence of greater 
variability in these data, and the more limited 
downward range of observed changes.
The other Class 1 genes were aspAT, with a 
similar function as TAT, ASS, one of the ﬁ  ve urea 
cycle enzymes and MDH, a citric acid cycle 
enzyme that catalyzes the conversion of malate 
into oxaloacetate, thus facilitating recycling of 
the urea cycle by-product fumerate, which are 
shown in the urea cycle general schematic in 
Figure 1. The dynamic proﬁ  le for aspAT (Fig. 5), 
known to be regulated by CS (Garlatti et al. 1996; 
Pave-Preux et al. 1988) resembled TAT, however, 
incorporation of a capacity-limited stimulation by 
DR(N) seemed to provide the best ﬁ  t for the data.
The action of CS on ASS and MDH are known 
to be secondary (Husson et al. 2003; Recupero et al. 
1986; Ulbright and Snodgrass, 1993). Bourgeois 
et al. reported dose-dependent increase in ASS 
mRNA expression in cultured rat hepatocytes which 
could be completely abolished by actinomycin D 
indicating involvement of the synthesis of some 
secondary factors in this regulation (Bourgeois et al. 
1997). The MDH has also been reported to be sec-
ondarily regulated by CS by potentiating the bind-
ing capacity of T3 receptors since CS action on 
MDH in thyroidectomized animals was minimal 
(Recupero et al. 1983; Recupero et al. 1986). 
However, our current in vivo datasets precluded 
addition of such secondary factors and therefore 
for simplicity Model B was used to capture both 
these enzyme inductions. For both ASS and MDH, 
however, the general patterns of the stimulation 
were quite different than TAT or aspAT. While the 
acute time proﬁ  les for ASS and MDH yielded a 
somewhat delayed and prolonged stimulation 
(lower degradation rates, 0.15 and 0.08 hr
−1 
compared to TAT and aspAT, 0.506 and 0.81 hr
−1), 
chronic infusion proﬁ  les for these two genes did 
not follow the apparent tolerance phenomenon 
visible in the chronic DR(N) proﬁ  le (Fig. 4). Rather 
the message seemed to remain up-regulated during 
the entire period of seven days (Fig. 5) indicating 
somewhat higher sensitivity to DR(N) compared to 
aspAT or TAT. The estimated values of the SC50 
parameters for these two genes (Model B) agreed 
with this observation, almost 15–20 fold 
(3.2–3.5 nM) lower than the steady-state DR(N) 
after chronic MPL (57 nM) compared to the higher 
estimated value for aspAT (191.5 nM).
Reports in the literature show CS-mediated 
direct or indirect increases in all three genes of 
Class 2, i.e. ASL, CEBP-β and ODC (Chowdhury 
et al. 1996; Hirvonen et al. 1988; Matsuno et al. 
1996; Nebes and Morris, 1988). Although our acute 
dataset predominantly showed up-regulation for 
these genes, chronic proﬁ  les indicated biphasic 
responses, especially for ODC and CEBP-beta. 
The initial increase in these messages was followed 
by a down-regulation up to or close to their baseline 
followed by a delayed increase. This was similar 
to the Class 1 genes suggesting a possible existence 
of a negative feedback regulator limiting the degree of 
increase of the message during chronic infusion of 
MPL. Models with a secondary mediator arising 
from the message itself regulating the initial 
increase would probably be most mechanistic; 
however, model convergence could not be achieved 
Table 5. Estimated pharmacodynamic parameters for Class 4 genes.
Parameters Deﬁ  nitions  GR  CA  GA
     Estimate  (CV%) 
kdgr,GR (h
−1)  Loss rate of gene  0.16 (21.8)  1.39 (27.6)  0.13 (12.2)
IC50 (fmol/mg  DR(N) for half-  162.8 (36.8)  385.1 (14.9)  14.92 (56)
protein)  maximal inhibition
SF  Scaling factor  1.09 (40.6)  –  –
GRm0,acute Baseline-Acute  1.0  (ﬁ  xed)  1 (ﬁ  xed)  1 (ﬁ  xed)
GRm0,chronic Baseline-Chronic  1.26  (8.9)  –  –17
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with such a model. ASL, one of the ﬁ  ve urea-cycle 
enzymes known to be secondarily regulated by CS, 
showed similar proﬁ  le as TAT or aspAT, however 
incorporation of the biosignal (Model C) was nec-
essary for satisfactory ﬁ  tting of the data.
An important transcription factor CEBP-β, 
contains a GRE in its promoter region and has been 
postulated to be one of the primary mediators of 
glucocorticoid effects on urea cycle enzymes in 
the liver, especially arginase and CPS. This chain 
of effects, i.e. of stimulation of CEBP-β by CS and 
in turn delayed stimulation of ARG and CPS by 
CEBP-β could be nicely captured for the acute 
dataset (results not shown); however, this model 
could not be implemented for the chronic dataset 
where the regulation seemed to be more complex, 
perhaps due to the involvement of multiple regula-
tory factors.
Class 3 contains the largest number of genes 
among all the classes (including three of the ﬁ  ve 
main urea cycle enzymes) predominantly showing 
a biphasic response, usually a rapid down-
regulation followed by an up-regulation, which 
could generally be described by Model D or E. 
Such a phenomenon is not surprising for CS since 
they may induce or inhibit the same gene depend-
ing on other regulatory proteins/transcription fac-
tors that are already present on the DNA control 
regions (Alberts et al. 2001). Since the up-
regulation was somewhat delayed for all the genes, 
both models assume the increase is mediated by a 
biosignal.
Although most of the reports in the literature 
suggest an inhibitory effect of CS on OTC in fetal 
as well as in adult rats (Gautier et al. 1985; Gautier 
et al. 1977; Ulbright and Snodgrass, 1993), we 
observed a subtle and delayed up-regulation in this 
gene after both acute and chronic MPL. As has 
been mentioned in the previous section, the coor-
dinated regulation of CS on CPS (the ﬁ  rst enzyme 
of the ornithine cycle, converts ammonia, originat-
ing from amino acid degradation, into urea) or 
arginase (the last enzyme of the cycle) via 
CEBP-β could not be applied to the chronic data-
set and thus these two genes were modeled 
independently of CEBP-β. Arginase and GDH 
seemed to show saturability in stimulation by the 
biosignal similar to a few of Class 1 genes. 
Although this phenomenon could be described by 
Model E, the precision of the estimated parameters 
was poor perhaps because of over-parameterization 
of the model and inadequate data thus limiting 
the capability of the estimation, especially the 
capacity-limited parameters such as SC50.
Class 4B genes, unlike Class 3 genes, do not 
show any delayed stimulation after acute MPL, 
however chronic dosing predominantly showed 
delayed up-regulation (glutaminase, involved in 
interconversion of two amino acids, glutamine and 
glutamate) or a biphasic response (carbonic anhy-
drase, responsible to form the bicarbonate ion from 
carbon dioxide from the Kreb’s cycle for the ﬁ  rst 
step of urea cycle) suggesting differential regula-
tion between acute and chronic dosing. Not much 
information is available regarding CS regulation 
of these two genes in the literature; however, initial 
investigation of the acute dataset showing down-
regulation only was surprising to us owing to the 
fact that CS treatment seemed to increase most of 
the genes related to the urea cycle either instanta-
neously or with a delay, which could be clearly 
observed only with chronic dosing for these two 
genes.
An important component of our analysis of both 
acute and chronic dosing of MPL was the necessity 
of including a scaling factor for the chronic dataset. 
Since this factor was only included in the chronic 
dataset (refer to Eq. 17), a value of greater than 1.0 
signiﬁ  ed greater sensitivity for the chips for the 
chronic dataset. Two different chips were used for 
the two treatment groups and data generated from 
them may not always produce concordant results. 
In general signal values tend to be higher for the 
majority of RAE-230A probe sets relative to the 
corresponding probe sets on RG-U34 suggesting 
a need for a scaling factor to accommodate this 
discordance. It was suggested by Affymetrix that 
the newer 230A chip is most likely to outperform 
the RG-U34 probe set when both magnitude of 
signal and responsiveness to a biologically diverse 
tissue panel are evaluated. The 230A chips were 
superior in 51% of the probe sets, 5.7% of the 
probes seemed to have higher signals in RG-U34 
chips, and less than 50% of the probes had equiv-
alent signals.
Consistent with the physiological role of gluco-
corticoids in stimulating gluconeogenesis/urea 
cycle activity, most urea cycle genes exhibited a 
general enhanced expression following CS 
treatment. However, this rich time series data set 
illustrates that examination of changes in gene 
expression at a single time following drug admin-
istration can be misleading as to magnitude or even 
direction of change. For example, if a gene such as 18
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OTC which exhibits a complex pattern is examined 
at an early time following acute administration, one 
would conclude down-regulation by CS. On the 
other hand, if later time points were examined up-
regulation is evident. This study also illustrates that 
time of exposure to drug (i.e. acute versus chronic 
treatment) is an important consideration to inter-
pretation of the effects of CS on gene expression. 
Chronic exposure to CS in some cases results in 
more complex biphasic patterns of expression not 
evident following acute exposure, indicating prob-
able secondary factors in control of expression. PD 
modeling can reveal insights into the complexities 
of mechanisms of gene regulation beyond simple 
up- or down-regulation by the drug.
In conclusion, endogenous and exogenous 
corticosteroids affect many physiological pro-
cesses. Studying each pathway individually is more 
rigorous and quantitative using techniques such as 
Quantitative Real-Time PCR, however, it is more 
time consuming and laborious. Although chal-
lenges in proper analysis and understanding of 
microarray results have emerged since the technol-
ogy evolved rapidly over the years, we were able 
to use this plethora of data to understand and ana-
lyze the underlying mechanism of various bio-
logical processes by using our mechanism-based 
PD models. The proposed models, while often 
premised on obvious mechanisms and supported 
by literature ﬁ  ndings, also present testable hypoth-
eses that can be examined in more extensive stud-
ies of speciﬁ  c genes.
Note
*Supported by Grant GM24211 from the National 
Institute of Health
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